pp-276 Suppositories
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Infectious disease
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Antimicrobial
Route & form: Vaginal Suppository
Differentiation: it is a peptide drug developed for the treatment of vaginal fungal and bacterial infections, has completed Phase I clinical studies for colpomycosis, bacterial vaginosis, and mixed vaginitis in Australia and China. Ongoing Phase II trials in China and the U.S.
Manufacturer #39348
National high-tech biopharmaceutical enterprise established in 2009, specializing in Rx peptide drugs and PROTAC-based targeted protein degrader development and manufacturing. Portfolio spans injectable and solid dosage form products for oncology and bacterial infections. Advances a targeted degrader and peptide pipeline with a global regulatory strategy.
None